151 related articles for article (PubMed ID: 25274697)
1. Idelalisib approved for trio of blood cancers.
Cancer Discov; 2014 Oct; 4(10):OF6. PubMed ID: 25274697
[No Abstract] [Full Text] [Related]
2. Idelalisib approved for three blood cancers.
Traynor K
Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
[No Abstract] [Full Text] [Related]
3. Idelalisib: first global approval.
Markham A
Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
6. Promising results Halt phase III studies of idelalisib.
Inman S
Am J Manag Care; 2014 Feb; 20(2 Spec No.):E9. PubMed ID: 25764575
[No Abstract] [Full Text] [Related]
7. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib has activity in mantle cell lymphoma.
Cancer Discov; 2014 May; 4(5):OF8. PubMed ID: 24795031
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib: targeting PI3Kδ in B-cell malignancies.
Gilbert JA
Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
[No Abstract] [Full Text] [Related]
10. Discussion: Managing Risk When Using Idelalisib.
Coutre SE; Burger JA; Pagel JM
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):13. PubMed ID: 27168205
[No Abstract] [Full Text] [Related]
11. [CAL-101,a novel agent of targeted therapy in hematological malignancies].
Li CJ; Zhang Q; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):530-3. PubMed ID: 24763037
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.
Brown JR; Zelenetz A; Furman R; Lamanna N; Mato A; Montillo M; O'Brien S; Dubowy R; Gu L; Munugalavadla V; Robak T; Hillmen P
Leukemia; 2020 Dec; 34(12):3404-3407. PubMed ID: 32655145
[No Abstract] [Full Text] [Related]
13. Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.
Reda G; Cassin R; Artoni A; Fattizzo B; Lecchi A; La Marca S; Bucciarelli P; Levati GV; Peyvandi F; Cortelezzi A
Br J Haematol; 2018 Dec; 183(5):825-828. PubMed ID: 29315493
[No Abstract] [Full Text] [Related]
14. Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report.
Gabrielli G; Broccoli A; Pellegrini C; Argnani L; Cavo M; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e15-e17. PubMed ID: 31711891
[No Abstract] [Full Text] [Related]
15. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2015 Oct; 373(16):1580-2. PubMed ID: 26466009
[No Abstract] [Full Text] [Related]
16. [Polymicrobial lung infection associated with idelalisib administration].
Rodríguez-Ferreras A; Velasco-Roces L; Lázaro-López E; Zapico-García I
Farm Hosp; 2018 Jan; 42(1):25-26. PubMed ID: 29306311
[No Abstract] [Full Text] [Related]
17. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity.
Castillo JJ; Gustine JN; Meid K; Dubeau T; Yang G; Xu L; Hunter ZR; Treon SP
Leuk Lymphoma; 2017 Apr; 58(4):1002-1004. PubMed ID: 27562445
[No Abstract] [Full Text] [Related]
18. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia.
Lafon-Desmurs B; Monsel G; Leblond V; Papo M; Caumes E; Fekkar A; Jaureguiberry S
Med Mal Infect; 2017 Jun; 47(4):293-296. PubMed ID: 27818019
[No Abstract] [Full Text] [Related]
19. Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.
Bleckmann A; Dierks S; Schildhaus HU; Hellige N; Bacher U; Trümper L; Wulf G
Ann Hematol; 2021 Jan; 100(1):277-279. PubMed ID: 32193631
[No Abstract] [Full Text] [Related]
20. Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Morschhauser F; Dyer MJS; Walter HS; Danilov AV; Ysebaert L; Hodson DJ; Fegan C; Rule SA; Radford J; Cartron G; Bouabdallah K; Davies AJ; Spurgeon S; Rajakumaraswamy N; Li B; Humeniuk R; Huang X; Bhargava P; Jürgensmeier JM; Salles G
Leukemia; 2021 Jul; 35(7):2108-2113. PubMed ID: 33328591
[No Abstract] [Full Text] [Related]
[Next] [New Search]
